Wilms’ tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN)

Christian Ottensmeier,1* Megan Bowers,2 Debbie Hamid,2 Tom Maishman,2 Scott Regan,2 Wendy Wood,2 Angelica Cazaly1 and Louise Stanton2

1Cancer Research UK Centre, Southampton University Hospital NHS Foundation Trust and University of Southampton, Southampton, UK
2Southampton Clinical Trials Unit MP131, Southampton General Hospital, Southampton, UK

*Corresponding author

Declared competing interests of authors: none

Published April 2016
DOI: 10.3310/eme03030

Plain English summary

The WIN Phase II non-randomised clinical trial Efficacy and Mechanism Evaluation 2016; Vol. 3: No. 3 DOI: 10.3310/eme03030

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

The Wilms’ tumour antigen 1 (WT1) Immunity via deoxyribonucleic acid (DNA) (WIN) study tested a possible vaccine treatment for patients with chronic myeloid leukaemia (CML) and acute myeloid leukaemia (AML). The treatment is directed at a molecule called WT1, which helps the survival of leukaemia cells. The vaccine also contains a small piece of genetic information from the tetanus bacterium, Clostridium tetani, which, linked to the gene element from WT1, is designed to boost the immune system to make white blood cells (lymphocytes) that can see and kill leukaemia cells. During the study, two types of molecules in the blood that are markers for leukaemia were measured: one is WT1 itself, the other is called BCR–ABL (breakpoint cluster region–Abelson murine leukaemia viral oncogene homolog 1). The vaccine was administered with a new type of injection called electroporation, designed to make the vaccine work better.

Twelve patients with CML were vaccinated. It was disappointing that the study was not completed for various reasons, the main one being slow recruitment. The levels of BCR–ABL were found to be reduced in one patient, whereas the levels of WT1 were reduced in another patient. The vaccine was well tolerated and there were no safety concerns. Immune response was evaluable in 10 patients. All responded to the tetanus component of the vaccine; 70% also made immune responses [CD8+ (cluster of differentiation 8)-positive T lymphocytes] to WT1. The vaccine had stimulated immune responses as we had hoped. Evaluation of the p.DOM–WT1 vaccines in AML remains clinically attractive and combination of the DNA vaccine with booster strategies is in development in the laboratory.
Criteria for inclusion in the Efficacy and Mechanism Evaluation journal

Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

EME programme

The Efficacy and Mechanism Evaluation (EME) programme was set up in 2008 as part of the National Institute for Health Research (NIHR) and the Medical Research Council (MRC) coordinated strategy for clinical trials. The EME programme is broadly aimed at supporting ‘science driven’ studies with an expectation of substantial health gain and aims to support excellent clinical science with an ultimate view to improving health or patient care.

Its remit includes evaluations of new treatments, including therapeutics (small molecule and biologic), psychological interventions, public health, diagnostics and medical devices. Treatments or interventions intended to prevent disease are also included.

The EME programme supports laboratory based or similar studies that are embedded within the main study if relevant to the remit of the EME programme. Studies that use validated surrogate markers as indicators of health outcome are also considered.

For more information about the EME programme please visit the website: http://www.nets.nihr.ac.uk/programmes/eme

This report

The research reported in this issue of the journal was funded by the EME programme as project number 08/99/24. The contractual start date was in January 2011. The final report began editorial review in March 2015 and was accepted for publication in October 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Ottensmeier et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
**Efficacy and Mechanism Evaluation Editor-in-Chief**

**Professor David Crossman**  Bute Professor of Medicine and Dean and Head of Faculty of Medicine, University of St Andrews, and Honorary Consultant Cardiologist, NHS Fife Health Board, UK

**NIHR Journals Library Editor-in-Chief**

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

**NIHR Journals Library Editors**

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke**  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Peter Davidson**  Director of NETSCC, HTA, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Professor Elaine McColl**  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

**Professor John Norrie**  Health Services Research Unit, University of Aberdeen, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board:
www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** nihredit@southampton.ac.uk